SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

Leukemia

Volumn 25, Issue 11, 2011, Pages 1751-1759

  Hart, S ^a   Goh, K C ^a   Novotny Diermayr, V ^a   Hu, C Y ^a   Hentze, H ^a   Tan, Y C ^a   Madan, B ^a   Amalini, C ^a   Loh, Y K ^a   Ong, L C ^a   William, A D ^a   Lee, A ^a   Poulsen, A ^a   Jayaraman, R ^a   Ong, K H ^b   Ethirajulu, K ^a   Dymock, B W ^a   Wood, J W ^a  

^a Singapore Science Park II   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

JAK2; lymphoma kinase inhibitor; myelofibrosis; SB1518

Indexed keywords

JANUS KINASE 2 INHIBITOR; MACROCYCLIC COMPOUND; PYRIMIDINE; STAT PROTEIN;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ERYTHROID CELL; FEMALE; HUMAN; LYMPHOMA; MOUSE; MYELOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

EID: 80755140046     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.148     Document Type: Article

References (33)

1. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117(Pt 8): 1281-1283. (Pubitemid 38559804)
2. Bennett M, Stroncek DF. Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med 2006; 4: 41.
3. Tickenbrock L, Muller-Tidow C, Berdel WE, Serve H. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006; 11: 153-165.
4. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discoveryFan underexploited structural class. Nat Rev Drug Discov 2008; 7: 608-624. (Pubitemid 351927725)
5. Younes A, Fanale MA, McLaughlin P, Copeland A, Zhu J, Faria SdC. Phase I study of a novel oral JAK-2 inhibitor sb1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. Blood 2010; 116: Abstract 2830.
6. Verstovsek S, Deeg HJ, Odenike O, Zhu J, Kantarjian HM, Estrov Z et al. Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis. Blood 2010; 116: Abstract 3082.
7. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 2006; 281: 18177-18183. (Pubitemid 44035617)
8. Manshouri T, Quintas-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J et al. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci 2008; 99: 1265-1273. (Pubitemid 351695096)
9. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22: 1114-1124. (Pubitemid 36313595)
10. Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther 2010; 9: 642-652.
11. van Boxel-Dezaire AH, Stark GR. Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol 2007; 316: 119-154.
12. Melzner I, Weniger MA, Bucur AJ, Bruderlein S, Dorsch K, Hasel C et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006; 118: 1941-1944.
13. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 2004; 24: 4955-4967. (Pubitemid 38668059)
14. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007; 21: 1658-1668. (Pubitemid 47086756)
15. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109-3117.
16. William A, Lee A, Blanchard S, Poulsen A, Teo E, Nagaraj H et al. Discovery of the macrocycle SB1518, a potent JAK2/FLT3 inhibitor for the treatment of myelofibrosis and lymphoma. J Med Chem 2011; dx.doi.org/10.1021/ jm200326p.
17. Tefferi A. How I treat myelofibrosis. Blood 2011; 117: 3494-3504.
18. Grandage VL, Everington T, Linch DC, Khwaja A. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006; 135: 303-316. (Pubitemid 44484837)
19. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the 'gatekeeper door': exploiting the active kinase conformation. J Med Chem 2010; 53: 2681-2694.
20. Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006; 107: 176-183. (Pubitemid 43053540)
21. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109: 4924-4929. (Pubitemid 46827790)
22. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murinemyeloproliferative neoplasms. Blood 2010; 115: 5232-5240.
23. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311-320. (Pubitemid 351446195)
24. Verstovsek S, Pardanani AD, Shah NP, Sokol L, Wadleigh M, Gilliland DG et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2007; 110: Abstract 553.
25. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25: 2679-2684.
26. Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B et al. Regulation of JAK2 by miR-135a: prognostic impact in classical Hodgkin lymphoma. Blood 2009; 114: 2945-2951.
27. Joos S, Granzow M, Holtgreve-Grez H, Siebert R, Harder L, Martin-Subero JI et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer 2003; 103: 489-495. (Pubitemid 36020223)
28. Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009; 22: 476-487.
29. Younes A, Fanale M, McLaughlin P, Copeland AR, Faria SdC, Wood J et al. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity. Blood 2009; 114: Abstract 588.
30. Cheson BD. Staging and evaluation of the patient with lymphoma. Hematol Oncol Clin North Am 2008; 22: 825-837, vii-viii.
31. Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Rohrs S et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 2008; 22: 2169-2175.
32. Hart S, Goh KC, Tan Y, Chithra A, Wood J. Pharmacodynamic (PD) biomarker assay validation for SB1518, a novel oral JAK2 inhibitor in phase I clinical trials for advanced leukemias, myeloproliferative diseases and lymphoma. Blood 2009; 114: Abstract 1888.
33. Verstovsek S, Odenike O, Scott B, Estrov Z, Cortes J, Thomas D et al. Phase I dose escalation trial of SB1518, a novel JAK2-FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-ET/post-PV myelofibrosis. Blood 2009; 114: abstract 3905.